apnea has been researched along with Retrolental Fibroplasia in 45 studies
Apnea: A transient absence of spontaneous respiration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 9.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| "To determine the incidence and risk factors of postoperative apnea in premature infants who received general anesthesia for cryotherapy or laser photocoagulation for treatment of retinopathy of prematurity (ROP) at Queen Sirikit National Institute of Child Health." | 7.80 | The incidence and risk factors of apnea in premature infants underwent general anesthesia for cryotherapy or laser photocoagulation for treatment of retinopathy of prematurity at Queen Sirikit National Institute of Child Health. ( Attachoo, A; Chongarunngamsang, W; Horatanaruang, D; Lauhsattana, S, 2014) |
| " The infants developed severe apnea and bradycardia at the end of the ROP examinations." | 7.75 | Apnea and bradycardia in two premature infants during routine outpatient retinopathy of prematurity screening. ( Kaufman, LM; Wood, MG, 2009) |
| "Growth, neurologic, and ophthalmologic assessments were done in 21 low-birth-weight infants given caffeine for neonatal apnea and in 21 matched control infants." | 7.66 | Sequelae of caffeine treatment in preterm infants with apnea. ( Aranda, JV; Gunn, TR; Metrakos, K; Riley, P; Willis, D, 1979) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 5.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| " Infants in the restrictive-transfusion group were more likely to have intraparenchymal brain hemorrhage or periventricular leukomalacia, and they had more frequent episodes of apnea, including both mild and severe episodes." | 5.11 | Randomized trial of liberal versus restrictive guidelines for red blood cell transfusion in preterm infants. ( Bell, EF; Cress, GA; Johnson, KJ; Kromer, IJ; Mahoney, LT; Mock, DM; Seward, VJ; Strauss, RG; Widness, JA; Zimmerman, MB, 2005) |
| ", a possible improved cognition of infants at 18-21 months' corrected age and a reduction of apnea." | 5.01 | What Is New about Transfusions for Preterm Infants? An Update. ( Kirpalani, H; Whyte, RK, 2019) |
| "Apnea of prematurity (AOP) is a common and pervasive problem in very low birth weight infants." | 4.98 | Caffeine: an evidence-based success story in VLBW pharmacotherapy. ( Dobson, NR; Hunt, CE, 2018) |
| " Despite aggressive respiratory support including mechanical ventilation, continuous positive airway pressure, oxygen and caffeine therapy to reduce apnea and accompanying intermittent hypoxemia, the incidence of intermittent hypoxemia events continues to increase during the first few months of life." | 4.93 | Cardiorespiratory events in preterm infants: interventions and consequences. ( Di Fiore, JM; Gauda, E; MacFarlane, P; Martin, RJ; Poets, CF, 2016) |
| "Premature infants often have serious problems, such as anemia, retinopathy, hearing loss and apnea, before and after discharge from the neonatal intensive care unit." | 4.78 | The neonatal ICU graduate: Part I. Common problems. ( Hulseman, ML; Norman, LA, 1992) |
| " Premature infants often require outpatient care for bronchopulmonary dysplasia, apnea, retinopathy of prematurity, intraventricular hemorrhage, hearing loss, hypothyroxinemia, anemia, neurodevelopmental sequelae, assessment of growth and nutrition, immunizations, and psychosocial stress." | 4.77 | Continuing care for the preterm infant after dismissal from the neonatal intensive care unit. ( Berseth, CL; Swanson, JA, 1987) |
| " These factors (immaturity, hyperoxia, hypoxia, blood transfusions, intraventricular hemorrhage, apnea, infection, hypercarbia, hypocarbia, patent ductus arteriosus, prostaglandin synthetase inhibitors, vitamin E deficiency, lactic acidosis, prenatal complications, genetic factors) may all be present in an infant." | 4.76 | A reexamination of the role of oxygen in retrolental fibroplasia. ( Dangman, B; Lucey, JF, 1984) |
| "346), apnea (OR = 2." | 3.88 | Retinopathy of Prematurity Among Very Low-Birth-Weight Infants in China: Incidence and Perinatal Risk Factors. ( Mu, D; Qu, Y; Tong, Y; Wu, T; Xia, B; Zhang, L, 2018) |
| " Caffeine is frequently used for apnea of prematurity." | 3.83 | Atrial arrhythmia after newborn eye exam, to caffeine or not to caffeine? ( Ahmad, A; Klein, B; Mondal, T, 2016) |
| "To determine the incidence and risk factors of postoperative apnea in premature infants who received general anesthesia for cryotherapy or laser photocoagulation for treatment of retinopathy of prematurity (ROP) at Queen Sirikit National Institute of Child Health." | 3.80 | The incidence and risk factors of apnea in premature infants underwent general anesthesia for cryotherapy or laser photocoagulation for treatment of retinopathy of prematurity at Queen Sirikit National Institute of Child Health. ( Attachoo, A; Chongarunngamsang, W; Horatanaruang, D; Lauhsattana, S, 2014) |
| "When asked to address the above question, findings that appeared to be among the most relevant included (1) interventions in the delivery room directed at supporting the physiological transition from intrauterine to extrauterine life rather than actively intervening in it; (2) recent data suggesting that keeping extremely low-gestational age neonates at a pulse oximeter saturation (SpO(2)) of 91-95% would increase their chances of survival compared with aiming for lower SpO(2) values; (3) using caffeine citrate in infants <1250 g with apnoea of prematurity improves neurodevelopmental outcome; (4) injecting antivascular epithelial growth factor into the vitreous seems to be an effective treatment for retinopathy of prematurity and (5) moderate hypothermia for perinatal hypoxic-ischaemic encephalopathy increases the likelihood of survival without neurological impairment." | 3.79 | What are the main research findings during the last 5 years that have changed my approach to clinical practice? ( Poets, CF, 2013) |
| "Apnea events increased significantly (P = ." | 3.77 | Physiologic effects of retinopathy of prematurity screening examinations. ( Green, A; Jeffs, DA; Mitchell, AJ; Roberson, PK, 2011) |
| "001), apnea (P=0." | 3.75 | Retinopathy of prematurity in a tertiary care center--incidence, risk factors and outcome. ( Chaudhari, S; Kadam, S; Kamat, A; Patwardhan, V; Vaidya, U, 2009) |
| " The infants developed severe apnea and bradycardia at the end of the ROP examinations." | 3.75 | Apnea and bradycardia in two premature infants during routine outpatient retinopathy of prematurity screening. ( Kaufman, LM; Wood, MG, 2009) |
| " On univariate analysis, gestation < or = 32 weeks, anemia, Blood transfusions, apnea and exposure to oxygen significantly increased the risk of developing ROP." | 3.69 | Retinopathy of prematurity: incidence and risk factors. ( Battu, RR; Rekha, S, 1996) |
| " For the 12 procedures performed on 11 infants who were not being mechanically ventilated at the time of cryotherapy, four infants had no complications, three infants had minor respiratory deteriorations, and five infants required positive pressure ventilation for severe apnea and bradycardia episodes (one just after narcotic administration, four during the procedure)." | 3.68 | Respiratory complications associated with cryotherapy in premature infants. ( Batton, DG; Ivery, P; Trese, M, 1992) |
| " Of 32 possible risk factors examined, the factors significantly associated with ROP were: apnea with mask and bag ventilation; prolonged parenteral nutrition; number of blood transfusions; and episodes of hypoxemia, hypercarbia, and hypocarbia." | 3.66 | Retinopathy of prematurity: incidence and risk factors. ( Ben-Sira, I; Krikler, R; Nissenkorn, I; Reisner, SH; Shohat, M; Yassur, Y, 1983) |
| "001); apnea requiring bag and mask resuscitation with oxygen (P less than ." | 3.66 | Risk factors in retrolental fibroplasia. ( Aranda, JV; Easdown, J; Gunn, TR; Outerbridge, EW, 1980) |
| "Growth, neurologic, and ophthalmologic assessments were done in 21 low-birth-weight infants given caffeine for neonatal apnea and in 21 matched control infants." | 3.66 | Sequelae of caffeine treatment in preterm infants with apnea. ( Aranda, JV; Gunn, TR; Metrakos, K; Riley, P; Willis, D, 1979) |
| "Retinopathy of prematurity was detected in 10." | 1.35 | Risk factors for retinopathy of prematurity in six neonatal intensive care units in Beijing, China. ( Chen, Y; Gilbert, C; Jiang, YR; Li, XX; Liang, JH; Yin, H; Zhao, MW, 2008) |
| "Vomiting was present in 4% of the newborns, gastric aspirates in 22% and apnoeas in 41% after the examination." | 1.32 | Screening for retinopathy of prematurity: is it painful? ( Belda, S; De la Cruz, J; Pallás, CR; Tejada, P, 2004) |
| "Retrolental fibroplasia is a condition that principally affects low birth weight premature babies in whom oxygen therapy has not been adequately controlled." | 1.26 | [Present status of retrolental fibroplasia in France]. ( Bethenod, M; Gerhard, JP; Messer, J; Willard, D, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (42.22) | 18.7374 |
| 1990's | 5 (11.11) | 18.2507 |
| 2000's | 9 (20.00) | 29.6817 |
| 2010's | 12 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, T | 1 |
| Zhang, L | 1 |
| Tong, Y | 1 |
| Qu, Y | 1 |
| Xia, B | 1 |
| Mu, D | 1 |
| Dobson, NR | 1 |
| Hunt, CE | 1 |
| Tan, JBC | 1 |
| Dunbar, J | 1 |
| Hopper, A | 1 |
| Wilson, CG | 1 |
| Angeles, DM | 1 |
| Kirpalani, H | 1 |
| Whyte, RK | 1 |
| Zhang, Q | 1 |
| Zhao, H | 1 |
| Feng, Y | 1 |
| Attachoo, A | 1 |
| Horatanaruang, D | 1 |
| Chongarunngamsang, W | 1 |
| Lauhsattana, S | 1 |
| Di Fiore, JM | 1 |
| Poets, CF | 2 |
| Gauda, E | 1 |
| Martin, RJ | 1 |
| MacFarlane, P | 1 |
| Reid, B | 1 |
| Wang, H | 1 |
| Guillet, R | 1 |
| Macintosh, JLB | 1 |
| Huggins, LJ | 1 |
| Eden, LM | 1 |
| Merrill, KC | 1 |
| Luthy, KEB | 1 |
| Ahmad, A | 1 |
| Mondal, T | 1 |
| Klein, B | 1 |
| Chaudhari, S | 1 |
| Patwardhan, V | 1 |
| Vaidya, U | 1 |
| Kadam, S | 1 |
| Kamat, A | 1 |
| Wood, MG | 1 |
| Kaufman, LM | 1 |
| Mitchell, AJ | 1 |
| Green, A | 1 |
| Jeffs, DA | 1 |
| Roberson, PK | 1 |
| TIZARD, JP | 2 |
| Kim, TI | 1 |
| Sohn, J | 1 |
| Pi, SY | 1 |
| Yoon, YH | 1 |
| Belda, S | 1 |
| Pallás, CR | 1 |
| De la Cruz, J | 1 |
| Tejada, P | 1 |
| Gupta, VP | 1 |
| Dhaliwal, U | 1 |
| Sharma, R | 1 |
| Gupta, P | 1 |
| Rohatgi, J | 1 |
| Bell, EF | 1 |
| Strauss, RG | 1 |
| Widness, JA | 1 |
| Mahoney, LT | 1 |
| Mock, DM | 1 |
| Seward, VJ | 1 |
| Cress, GA | 1 |
| Johnson, KJ | 1 |
| Kromer, IJ | 1 |
| Zimmerman, MB | 1 |
| Schmidt, B | 1 |
| Roberts, RS | 1 |
| Davis, P | 1 |
| Doyle, LW | 1 |
| Barrington, KJ | 1 |
| Ohlsson, A | 1 |
| Solimano, A | 1 |
| Tin, W | 1 |
| Stevenson, DK | 1 |
| Chen, Y | 1 |
| Li, XX | 1 |
| Yin, H | 1 |
| Gilbert, C | 1 |
| Liang, JH | 1 |
| Jiang, YR | 1 |
| Zhao, MW | 1 |
| Shohat, M | 1 |
| Reisner, SH | 1 |
| Krikler, R | 1 |
| Nissenkorn, I | 1 |
| Yassur, Y | 1 |
| Ben-Sira, I | 1 |
| Lucey, JF | 1 |
| Dangman, B | 1 |
| François, J | 1 |
| Flynn, JT | 1 |
| Gunn, TR | 2 |
| Easdown, J | 1 |
| Outerbridge, EW | 2 |
| Aranda, JV | 3 |
| Clark, C | 1 |
| Gibbs, JA | 1 |
| Maniello, R | 1 |
| Rekha, S | 1 |
| Battu, RR | 1 |
| Jones, MD | 1 |
| Murton, LJ | 1 |
| Metrakos, K | 1 |
| Riley, P | 1 |
| Willis, D | 1 |
| Messer, J | 1 |
| Bethenod, M | 1 |
| Gerhard, JP | 1 |
| Willard, D | 1 |
| Fitzhardinge, PM | 1 |
| Pape, P | 1 |
| Arstikaitis, M | 1 |
| Boyle, M | 1 |
| Ashby, S | 1 |
| Rowley, A | 1 |
| Netley, C | 1 |
| Swyer, PR | 1 |
| Immonen, I | 1 |
| Hulseman, ML | 1 |
| Norman, LA | 1 |
| Batton, DG | 1 |
| Ivery, P | 1 |
| Trese, M | 1 |
| Tashiro, C | 1 |
| Matsui, Y | 1 |
| Nakano, S | 1 |
| Ueyama, H | 1 |
| Nishimura, M | 1 |
| Oka, N | 1 |
| Levitt, GA | 1 |
| Mushin, A | 2 |
| Bellman, S | 1 |
| Harvey, DR | 1 |
| Purohit, DM | 1 |
| Ellison, RC | 1 |
| Zierler, S | 1 |
| Miettinen, OS | 1 |
| Nadas, AS | 1 |
| Swanson, JA | 1 |
| Berseth, CL | 1 |
| Bates, JH | 1 |
| Burnstine, RA | 1 |
| Nicholson, A | 1 |
| Bowell, R | 1 |
| Gorman, WA | 1 |
| Alden, ER | 1 |
| Kalina, RE | 1 |
| Hodson, WA | 1 |
| Baum, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Apneic Oxygenation to Prevent Oxygen Desaturation During Intubation in the NICU[NCT05451953] | 110 participants (Anticipated) | Interventional | 2022-07-21 | Recruiting | |||
| Efficiency and Safety of Phenylephrine and Tropicamide Used in Premature Retinopathy[NCT03448640] | 60 participants (Actual) | Observational | 2016-01-15 | Completed | |||
| Intranasal Dexmedetomidine for Pain Management During Screening for Retinopathy of Prematurity: A Crossover Randomized Controlled Trial[NCT06067958] | Phase 3 | 30 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| Randomized Trial of Liberal Versus Restrictive Guidelines for Red Blood Cell Transfusion in Preterm Infants[NCT00369005] | 100 participants | Interventional | 1992-12-31 | Completed | |||
| A Prospective, Controlled Trial of Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea of Prematurity[NCT01911182] | Phase 2/Phase 3 | 7 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to Low recruitment rate) | ||
| Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants[NCT00182312] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1999-10-31 | Completed | ||
| Long-Term Effects On Sleep Of Methylxanthine Therapy For Apnea Of Prematurity[NCT01020357] | Phase 3 | 201 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [NCT01066728] | Phase 2/Phase 3 | 87 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| A Randomized, Placebo-controlled Trial of Early Caffeine in Preterm Neonates[NCT03086473] | Phase 4 | 24 participants (Actual) | Interventional | 2017-02-01 | Active, not recruiting | ||
| Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia[NCT05295784] | Phase 1 | 18 participants (Anticipated) | Interventional | 2024-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for apnea and Retrolental Fibroplasia
| Article | Year |
|---|---|
Caffeine: an evidence-based success story in VLBW pharmacotherapy.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Ductus Arteriosus, Patent; Enterocolitis, Necrot | 2018 |
What Is New about Transfusions for Preterm Infants? An Update.
Topics: Anemia, Neonatal; Apnea; Erythrocyte Transfusion; Erythropoietin; Evidence-Based Practice; Humans; I | 2019 |
Cardiorespiratory events in preterm infants: interventions and consequences.
Topics: Animals; Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Continuous Positive Airway | 2016 |
A reexamination of the role of oxygen in retrolental fibroplasia.
Topics: Anencephaly; Apnea; Carbon Dioxide; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Exchange Transfu | 1984 |
Mechanical ventilation in newborn infants with hyaline membrane disease;.
Topics: Acidosis; Apnea; Birth Weight; Bradycardia; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Gestatio | 1977 |
[Retinopathy of prematurity].
Topics: Apnea; Humans; Hypercapnia; Hypocapnia; Infant, Newborn; Oxygen; Retinopathy of Prematurity | 1991 |
The neonatal ICU graduate: Part I. Common problems.
Topics: Anemia; Apnea; Bronchopulmonary Dysplasia; Hearing Disorders; Humans; Infant; Infant, Low Birth Weig | 1992 |
Continuing care for the preterm infant after dismissal from the neonatal intensive care unit.
Topics: Anemia, Neonatal; Apnea; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Hearing Loss; Humans; Infa | 1987 |
Retrolental fibroplasia: management of oxygen therapy.
Topics: Apnea; Brain Diseases; Humans; Hyaline Membrane Disease; Infant, Newborn; Intubation, Intratracheal; | 1970 |
2 trials available for apnea and Retrolental Fibroplasia
| Article | Year |
|---|---|
Randomized trial of liberal versus restrictive guidelines for red blood cell transfusion in preterm infants.
Topics: Anemia; Apnea; Blood Donors; Brain Damage, Chronic; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; | 2005 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
34 other studies available for apnea and Retrolental Fibroplasia
| Article | Year |
|---|---|
Retinopathy of Prematurity Among Very Low-Birth-Weight Infants in China: Incidence and Perinatal Risk Factors.
Topics: Apnea; Birth Weight; Blood Transfusion; Bronchopulmonary Dysplasia; China; Ductus Arteriosus, Patent | 2018 |
Differential effects of the retinopathy of prematurity exam on the physiology of premature infants.
Topics: Apnea; Bradycardia; Female; Gastric Emptying; Heart Rate; Humans; Infant, Newborn; Infant, Premature | 2019 |
Laryngeal mask airway with pressure support ventilation vs. endotracheal tube with pressure controlled ventilation in preterm infants undergoing ROP surgery: A propensity score matching analysis of perioperative complications.
Topics: Anesthesia, General; Apnea; Female; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Very | 2019 |
The incidence and risk factors of apnea in premature infants underwent general anesthesia for cryotherapy or laser photocoagulation for treatment of retinopathy of prematurity at Queen Sirikit National Institute of Child Health.
Topics: Anesthesia, General; Apnea; Child; Cryotherapy; Female; Gestational Age; Humans; Incidence; Infant; | 2014 |
Apnea after Routine Eye Examinations in Premature Infants.
Topics: Apnea; Birth Weight; Bradycardia; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Ophth | 2017 |
Immunization Status of NICU Graduates at a Tertiary Care Children's Hospital.
Topics: Adrenal Cortex Hormones; Age Factors; Apnea; Bradycardia; Bronchopulmonary Dysplasia; Continuous Pos | 2017 |
Atrial arrhythmia after newborn eye exam, to caffeine or not to caffeine?
Topics: Apnea; Atrial Premature Complexes; Bradycardia; Caffeine; Central Nervous System Stimulants; Cyclope | 2016 |
Retinopathy of prematurity in a tertiary care center--incidence, risk factors and outcome.
Topics: Apnea; Birth Weight; Developing Countries; Female; Gestational Age; Humans; Incidence; India; Infant | 2009 |
Apnea and bradycardia in two premature infants during routine outpatient retinopathy of prematurity screening.
Topics: Apnea; Bradycardia; Diagnostic Techniques, Ophthalmological; Humans; Infant, Newborn; Neonatal Scree | 2009 |
What are the main research findings during the last 5 years that have changed my approach to clinical practice?
Topics: Apnea; Caffeine; Humans; Hypothermia, Induced; Hypoxia-Ischemia, Brain; Infant, Extremely Premature; | 2013 |
Physiologic effects of retinopathy of prematurity screening examinations.
Topics: Academic Medical Centers; Apnea; Arkansas; Female; Health Status; Humans; Infant, Newborn; Intensive | 2011 |
Physiologic effects of retinopathy of prematurity screening examinations.
Topics: Academic Medical Centers; Apnea; Arkansas; Female; Health Status; Humans; Infant, Newborn; Intensive | 2011 |
Physiologic effects of retinopathy of prematurity screening examinations.
Topics: Academic Medical Centers; Apnea; Arkansas; Female; Health Status; Humans; Infant, Newborn; Intensive | 2011 |
Physiologic effects of retinopathy of prematurity screening examinations.
Topics: Academic Medical Centers; Apnea; Arkansas; Female; Health Status; Humans; Infant, Newborn; Intensive | 2011 |
INDICATIONS FOR OXYGEN THERAPY IN THE NEWBORN.
Topics: Apnea; Asphyxia Neonatorum; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Oxygen; Ox | 1964 |
Postnatal risk factors of retinopathy of prematurity.
Topics: Apnea; Birth Weight; Disease Progression; Gestational Age; Humans; Infant, Newborn; Infant, Prematur | 2004 |
Screening for retinopathy of prematurity: is it painful?
Topics: Apnea; Birth Weight; Blood Pressure; Diagnostic Techniques, Ophthalmological; Gestational Age; Heart | 2004 |
Retinopathy of prematurity--risk factors.
Topics: Apnea; Female; Humans; Hyaline Membrane Disease; Incidence; India; Infant; Infant, Low Birth Weight; | 2004 |
On the caffeination of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Developmental Disabilities; Humans; Infant, Newb | 2007 |
Risk factors for retinopathy of prematurity in six neonatal intensive care units in Beijing, China.
Topics: Abruptio Placentae; Anemia; Apnea; Birth Weight; China; Female; Gestational Age; Humans; Hypoxia-Isc | 2008 |
Retinopathy of prematurity: incidence and risk factors.
Topics: Apnea; Carbon Dioxide; Female; Humans; Hypoxia; Infant, Low Birth Weight; Infant, Newborn; Male; Oxy | 1983 |
Risk factors for retrolental fibroplasia.
Topics: Apnea; Exchange Transfusion, Whole Blood; Humans; Hyaline Membrane Disease; Infant, Newborn; Infant, | 1983 |
Acute proliferative retrolental fibroplasia: multivariate risk analysis.
Topics: Analysis of Variance; Anemia; Apnea; Birth Weight; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; | 1983 |
Risk factors in retrolental fibroplasia.
Topics: Apnea; Birth Weight; Follow-Up Studies; Gestational Age; Humans; Infant, Newborn; Infant, Newborn, D | 1980 |
Blood transfusion: a possible risk factor in retrolental fibroplasia.
Topics: Apnea; Diseases in Twins; Exchange Transfusion, Whole Blood; Humans; Infant, Low Birth Weight; Infan | 1981 |
Retinopathy of prematurity: incidence and risk factors.
Topics: Analysis of Variance; Anemia; Apnea; Blood Transfusion; Cohort Studies; Cryosurgery; Follow-Up Studi | 1996 |
Sequelae of caffeine treatment in preterm infants with apnea.
Topics: Apnea; Caffeine; Child Development; Female; Follow-Up Studies; Humans; Infant, Low Birth Weight; Inf | 1979 |
[Present status of retrolental fibroplasia in France].
Topics: Apnea; Body Weight; France; Humans; Infant, Newborn; Infant, Premature, Diseases; Oxygen; Retinopath | 1979 |
Mechanical ventilation of infants of less than 1,501 gm birth weight: Health, growth, and neurologic sequelae.
Topics: Apnea; Birth Weight; Body Height; Child, Preschool; Female; Follow-Up Studies; Growth; Hemiplegia; H | 1976 |
Respiratory complications associated with cryotherapy in premature infants.
Topics: Apnea; Bradycardia; Cryosurgery; Humans; Infant; Infant, Newborn; Positive-Pressure Respiration; Ret | 1992 |
Respiratory outcome in extremely premature infants following ketamine anaesthesia.
Topics: Age Factors; Aminophylline; Anesthesia, Intravenous; Apnea; Birth Weight; Gestational Age; Humans; I | 1991 |
Outcome of preterm infants who suffered neonatal apnoeic attacks.
Topics: Apnea; Child, Preschool; Deafness; Developmental Disabilities; Humans; Infant; Infant, Newborn; Infa | 1988 |
Risk factors for retrolental fibroplasia: experience with 3,025 premature infants. National Collaborative Study on Patent Ductus Arteriosus in Premature Infants.
Topics: Anemia; Apnea; Birth Weight; Bronchopulmonary Dysplasia; Female; Histamine H1 Antagonists; Humans; I | 1985 |
Consequences of retinopathy of prematurity examinations. Case report.
Topics: Apnea; Female; Humans; Infant, Newborn; Ophthalmoscopy; Retinopathy of Prematurity | 1987 |
Occurrence of retinopathy of prematurity in a very low birthweight population.
Topics: Apnea; Humans; Infant, Low Birth Weight; Infant, Newborn; Respiration, Artificial; Retinopathy of Pr | 1985 |
Transient cataracts in low-birth-weight infants.
Topics: Acidosis; Ampicillin; Apgar Score; Apnea; Bicarbonates; Birth Weight; Blood Pressure; Body Temperatu | 1973 |
Ocular changes in premature babies receiving controlled oxygen therapy in the neonatal period.
Topics: Apnea; Humans; Infant, Newborn; Infant, Premature, Diseases; Ophthalmoscopy; Oxygen; Oxygen Inhalati | 1971 |